Search Results

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, provided first quarter 2024 financial results and business updates.

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis.

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN) announced today that preclinical data highlighting the potential for Surrozen’s antibody-based Wnt mimetic technologies to treat cornea endothelial damage and Dry Eye Disease (DED) were presented on May 7, 2024 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle.

Surrozen, Inc. (Nasdaq: SRZN) announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02786-2.

Surrozen, Inc. announced publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications.

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, provided an update on the Phase 1a clinical trial of SZN-043 in healthy volunteers and patients with cirrhosis.

Surrozen, Inc. announced that enrollment for the SZN-043 Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers is complete.